Kornimate/medical-research-clean huggingface dataset:
valuation of the low back pain treated with different types of active exercises in women

Conditions: Low Back Pain

Summary: the purpose of the study is determine whether the core stability exercise is more effective than the traditional back school for low back pain (lbp) in women.

the aim of this study is to check what kind of exercises are the best to treat lbp with regard to clinical improvements. the secondary objectives are: to determine which treatment is more effective in improving pain in the fewest sessions possible, to determine the involvement of inflammatory biomarkers in the development of pain and revalue the results after one month of having finishing treatment. the project is a longitudinal, single-blind and randomized study with two treatment groups: group 1: infrared light+ transcutaneous electrical nerve stimulation (tens) + core stability exercises. group 2: infrared light + transcutaneous electrical nerve stimulation (tens) + traditional back school. duration of treatment: 4 weeks. the participants will performe the exercises in 20 daily sessions (monday to friday) guided by a physiotherapist. following treatment with the physiotherapist, the participants should perform the exercises at home for 4 weeks at a rate of three times per week.

Eligibility criteria:
inclusion criteria: * women aged 18 to 70 years. * diagnosis of back pain from a trauma. * untreated pain (except acetaminophen). * informed consent. exclusion criteria: * algic process in the lumbar spine of infectious, neoplastic, metastasis, osteoporosis, inflammatory arthritis or fractures. * cognitive impairment of any etiology. * exercise intolerance for any reason. * patients who have completed physical therapy in the last 3 months. * patients who have received infiltration injections in the last 6 weeks.

Keywords: low back pain core stability exercise back school tens infra- red light
efficacy and akathisia incidence of slow infusion metoclopramide

Conditions: Akathisia; Nausea

Summary: study objective: the purpose of this study is to compare the effects of metoclopramide administration in bolus versus slow infusion medications in ed patients complaining of nausea for the determination of the therapeutic effect and prevention of akathisia. methods: this was a prospective, randomized, double-blind trial. the investigation was held between 01 march 2007 and 01 may 2008, in the emergency department of pamukkale university faculty of medicine. the patients with moderate to severe nausea randomized and divided into two groups as for the previously planned administration type of drug. ten mg metoclopramide was administered in one group with slow infusion (sig) in 15 minutes, via 2 minutes bolus infusion (big) into the other group. whole procedure was observed, akathisia and nausea scores and vital changes were recorded.


Eligibility criteria:
inclusion criteria: * patients 18 through 65 years of age and 50-90 kg of weight who presented to the ed with primary or secondary complaints of moderate to severe nausea who not use of commonly accepted antiemetic within the previous 24 hours were eligible for this study. * their peripheral oxygen saturation level was 90% or over while respirating room air and free of any respiratory problems. exclusion criteria: * patients with mild symptoms of nausea * altered mental status * abnormal vital signs * any known allergy to the metoclopramide * previously enrolled in the study * known renal failure or insufficiency * gis hemorrhage, ileus and/or perforation * women who were pregnant and lactating * those with a history of epilepsy * admitted to the ed due to acute psychiatric symptoms * restless legs syndrome * parkinson * organic brain disease * phaeochromocytoma * patient with alcohol * anticholinergic, sedative, hypnotic, trankilizan, digoxin, cimetidine, tetracycline and levo-dopa use * presence of severe agitation akathisia can not be evaluated and uncooperative individuals.

Keywords: metoclopramide akathisia nausea vomiting antiemetic improvement of nausea
dietary fish protein in subjects with insulin resistance

Conditions: Insulin Resistance; Type 2 Diabetes

Summary: the objective of our research project is to determine the effects of fish protein, present in fish, on insulin sensitivity in insulin-resistant human individuals, and its mechanism of action on glucose metabolism. our hypothesis is that fish protein improves insulin sensitivity, glucose tolerance and plasma lipid profile through an improvement in a primary defect in insulin signaling in overweight and insulin-resistant subjects.

recent data show that cod protein prevents the development of insulin resistance in rats. dietary fish protein may also enhance insulin sensitivity in overweight insulin-resistant subjects by improving a primary defect in insulin signaling to pi 3-kinase, leading to reduced activation of the downstream effectors akt and pkc. to determine whether this is the case, we will study the effects of fish protein on insulin sensitivity in humans, and how it improves the ability of muscles to use glucose. such studies will help to advise individuals with insulin resistance or type 2 diabetes about eating fish.

Eligibility criteria:
inclusion criteria: * overweight or obese (bmi between 25 and 40 kg /m2) * waist circumference above 88 cm for women and 102 cm for men * fasting plasma insulin above 90 pmol/l * fasting plasma glucose below 7.0 mmol/l and 2-h plasma glucose below 11.1 mmol/l exclusion criteria: * individuals with diagnosed diabetes or any chronic, metabolic or acute disease * individuals who had a major surgery within the last 3 months * individuals who had a significant weight loss (±10%) within the last 6 months * individuals taking any medication known to affect lipid or glucose metabolism * subjects with dietary incompatibility with fish consumption (allergy, intolerance or dislike) and/or calcium supplementation * smokers

Keywords: cod protein insulin sensitivity plasma lipids glucose tolerance plasma inflammatory markers skeletal muscle insulin signaling type 2 diabetes humans
the burnout syndrome in emergency department triage nurses

Conditions: Burnout, Professional; Nurse's Role

Summary: assessment of burnout syndrome of triage nurses from emergency departments from cluj-napoca, romania.

this study is aiming at assessing the burnout syndrome amongst triage nurses working in the emergency departments in cluj-napoca. the study design is observational, prospective and multicentric. at this moment, there are 43 nurses covering triage shifts in the emergency clincial county hospital cluj and 18 more within emergency clinical hospital for children cluj-napoca. on average, these ed roughly attend 90.000 patients yearly. questionnaires are based on copenhagen burnout inventory, with additional clinical cases that require triage coding according to the romanian national triage protocol of 2016. each triage nurse will complete the questionnaire when beginning the triage shift and after a period of 2, 4 or 6 hours.

Eligibility criteria:
inclusion criteria: * ed nurse within emergency clinical county hospital cluj and emergency clinic hospital for children cluj-napoca. exclusion criteria: * triage experience of at least 1 year

Keywords: burnout syndrome triage nurse emergency department romania
a 36-week safety extension study of elnd005 as a treatment for agitation and aggression in alzheimer's disease

Conditions: Alzheimer's Disease

Summary: to evaluate the safety and tolerability of elnd005 treatment with up to 36 weeks exposure, in moderate to severe ad patients with agitation and aggression.


Eligibility criteria:
inclusion criteria: * complete week 12 visit of ag201 * both patient and study partner/caregiver are willing and able to participate in all scheduled evaluations and complete all required tests exclusion criteria: * is currently using any other investigational or experimental drugs or devices * has significant worsening of medical conditions or dementia such that it may preclude completion of this safety extension study

Keywords: agitation aggression ad patients
an sms intervention to improve adherence to stimulant medications in adults with adhd

Conditions: Attention Deficit/Hyperactivity Disorder

Summary: this study will assess the efficacy of the text messaging (sms-based) disease management intervention to improve adherence to stimulants in adults with attention deficit/hyperactivity disorder (adhd). participants in the study will receive customized text messages twice a day, every day, for a duration of 9 months. the text messages will include reminders to adhere to the individualized medication regimen, reminders to call their clinician for a prescription refill followed by reminders to pick up medication from the pharmacy, and educational reminders about adhd and its treatment.


Eligibility criteria:
inclusion criteria: * male and female adults 18 to 55 years * a diagnosis of diagnostic and statistical manual diploma in social medicine (dsm-v) attention deficit hyperactivity disorder based on clinical assessment * is starting stimulant medication or has begun treatment with stimulant medication within six months of study enrollment * proficient in english * has a cellular phone with text messaging capabilities and is interested in and willing to receive text messages exclusion criteria: * serious chronic medical or psychiatric condition that, in the investigator's opinion, puts the subject at risk for taking a stimulant * pregnant or nursing females * investigator and his/her immediate family * unwilling/unable to comply with study procedures

Keywords: attention deficit/hyperactivity disorder adhd sms intervention
an improvement project around staffs' influenza vaccine uptake

Conditions: Influenza Vaccination

Summary: to reach seasonal vaccination against influenza targets, university hospitals birmingham (uhb) already invites staff to take up the vaccination, and every november reminds staff that have not yet vaccinated to do so. the current protocol describes a randomized controlled trial (rct) in which staff will be sent different reminders, and the investigators will compare the proportion of staff that go on to vaccinate after receiving each reminder.

seasonal vaccination against influenza is recommended for nhs staff. , to increase vaccination rates, nhs england put forth a commissioning for quality and innovation goal for the 2018/2019 season of 75%. university hospitals birmingham nhs foundation trust (uhb) wants its vaccination rate to surpass this target. since staff get infected outside of the hospital and from patients staff vaccination does not provide significant 'herd immunity' to reach past targets, every september uhb already invites staff to take up the vaccination, and regularly reminds staff that have not yet vaccinated to do so. the current protocol describes a randomized controlled trial (rct) in which staff will be sent a different letter when first invited to receive vaccination, and we will compare the proportion of staff that go on to vaccinate after receiving each type of letter.. to conduct the rct the research team will design four letter styles. one factor will emphasize an authority figure inviting staff to vaccinate (the chief executive, who is also a doctor). the other factor will emphasize a competitive social norm describing vaccination rates in peer hospitals, including addenbrooke's, cambridge university hospitals (which has exemplary rates) see appendix a and across american hospitals (which also have high rates). letters will be sent to staff in the first week in october by uhb's communications team and they will be disseminated in a randomized fashion. the uow's role in this study is to advise the study's design and write-up the project for publication. uhb will approve the reminders, send the reminders, retrieve the data, and analyse the data. no individual-level data will be transferred across organizations. all individual-level data will be managed by authorized uhb employees, e.g., a uhb statistician will randomize staff to receive different reminders and analyze the data, and uhb's communication team to disseminate the reminders.

Eligibility criteria:
inclusion criteria: * all uhb staff eligible for the seasonal influenza vaccination are eligible for this study. (no patients are included)
the effect of tranexamic acid in endoscopic and microscopic ear surgery cases on surgeon satisfaction

Conditions: Middle Ear Disease

Summary: by using tranexamic acid, an antifibrinolytic drug, the aim is to prevent the restriction of the field of view of the surgical field due to bleeding in middle ear microscopic and endoscopic surgery operations in which controlled hypotension is applied, and therefore the prolongation of the surgical time, and to increase surgeon satisfaction.

after obtaining approval from our university and the turkish ministry of health's pharmaceutical and medical device agency and written consent from the patients, 100 patients who underwent middle ear surgery using controlled hypotension under general anesthesia will be included in the study. the study will be conducted in a randomized controlled, double-blind manner. patients between the ages of 18-65 and with american society of anesthesiologists (asa) scores i and ii will be included in the study. patients will be divided into two groups: intervention (m) and control (c). just before the operation begins, 10 mg/kg tranexamic acid (txa) will be administered to the intervention group in 100 ml of 0.9% physiological saline (sf) solution in 15 minutes. 100 ml of 0.9% sf solution will be sent to the control group in 15 minutes. at the end of the operation, the operator's quality of vision of the surgical field will be recorded by questioning the surgeon's satisfaction with the boezaart score and the surgeon satisfaction score.

Eligibility criteria:
inclusion criteria: * individuals between the ages of 18-65 * individuals with asa i (no additional disease) or asa ii (mild systemic disease) * those who do not have a disease such as thrombophilia or bleeding diathesis will be included in the study exclusion criteria: * patients with asa iii (those with uncontrolled chronic disease) or above * patients with cardiovascular disease, congestive heart failure, coronary artery disease, cerebrovascular insufficiency, renal or hepatic failure * patients with thrombophilia, bleeding diathesis, coagulation defects * pregnant patients * those with a history of any allergic reaction to tranexamic acid and its derivatives will be excluded from the study

Keywords: tranexamic acid controlled hypotension middle ear surgery
an efficacy and safety study of niraparib in men with metastatic castration-resistant prostate cancer and dna-repair anomalies

Conditions: Prostatic Neoplasms

Summary: the purpose of this study is to assess the efficacy, safety, and pharmacokinetics of niraparib in men with metastatic castration-resistant prostate cancer (mcrpc) and deoxyribonucleic acid (dna) repair anomalies.

this is a multicenter and open-label (participants and researchers are aware of the treatment that participants are receiving) study that consists of 4 phases: a prescreening phase for biomarker evaluation only, a screening phase, a treatment phase (cycle 1 day 1 and will continue until the study drug is discontinued), a follow-up phase (every 3 months after end of treatment visit), and a long-term extension phase (until participants no longer derive benefit from treatment or until further notification on different means of study treatment). participants will be monitored for safety during the study period, and up to 30 days after the last dose of study drug.

Eligibility criteria:
inclusion criteria: * histologically confirmed prostate cancer (mixed histology is acceptable, with the exception of the small cell pure phenotype, which is excluded) * received a taxane-based chemotherapy for the treatment of metastatic prostate cancer with evidence of disease progression on or after treatment, or discontinued from a taxane-based chemotherapy due to an adverse event * received a second-generation or later androgen receptor (ar)-targeted therapy (for example, abiraterone acetate plus prednisone, enzalutamide, apalutamide) for the treatment of metastatic prostate cancer with evidence of disease progression or non-metastatic castration-resistant prostate cancer with evidence of subsequent metastasis * biomarker-positive by at least one of the following criteria: (a) biallelic deoxyribonucleic acid (dna)-repair anomaly based on a sponsor validated blood or tissue assay; (b) germline pathogenic breast cancer gene (brca) 1 or brca2 by any test (somatic local results must be confirmed as positive by the sponsor-validated assay before dosing) * progression of metastatic prostate cancer in the setting of castrate levels of testosterone or history of bilateral orchiectomy at study entry exclusion criteria: * prior treatment with a poly (adenosine diphosphate \[adp\] ribose) polymerase (parp) inhibitor * prior platinum-based chemotherapy for the treatment of prostate cancer * known history or current diagnosis of myelodysplastic syndrome (mds)/acute myeloid leukemia (aml) * symptomatic or impending cord compression * symptomatic brain metastases

Keywords: prostate cancer crpc metastatic castrate-resistant prostate cancer prostate neoplasm galahad niraparib dna anomalies dna defect parp inhibitor parpi
efficacy, safety and tolerability of xbd173 in patients with generalized anxiety disorder

Conditions: Anxiety Disorders

Summary: this study will test the efficacy, safety and tolerability of xbd173 in the treatment of generalized anxiety disorder in patients.


Eligibility criteria:
inclusion criteria: * current doctor's diagnosis of generalized anxiety disorder * in need of psychiatric treatment * willingness to complete all aspects of the study exclusion criteria: * current doctor's diagnosis of major depression * history of schizophrenia or schizoaffective disorders * drug dependence within 2 months prior to study start for detailed information on eligibility, please contact the study center nearest to you (see below), or call 1-862-778-8300, or visit the following website: www.novartisclinicaltrials.com

Keywords: gad anxiety xbd173 generalized anxiety disorder
artemis proximal femoral nail for internal fixation of intertrochanteric femur fractures

Conditions: Intertrochanteric Fractures; Femoral Fracture; Femoral Neck Fractures

Summary: in february 2021, altior trauma innovations™ announced that it had received 501(k) fda approval for the artemis proximal femoral nail (pfn) system for internal fixation of intertrochanteric femur fractures. the objective of this pilot study is to evaluate safety, efficacy and feasibility of the artemis pfn implant for operative fixation of intertrochanteric femoral fractures, compared to matched historical control patients who received other implants.

intertrochanteric femur fractures are a common injury pattern seen after acute hip trauma, with a very high rate of morbidity and mortality particularly among elderly patients. cephalomedullary nail fixation has become a mainstay of treatment for both stable and unstable intertrochanteric fractures, offering greater stability than other options without replacing the native hip joint when possible. despite this, the incidence of fracture nonunion remains high, resulting in poor functional outcomes, higher healthcare costs, and conversion to hemi- or total hip arthroplasty. in february 2021, altior trauma innovations™ announced that it had received 501(k) fda approval for the artemis proximal femoral nail (pfn) system for internal fixation of intertrochanteric femur fractures. the artemis pfn implant offers several purported advantages over existing implants. it is manufactured with a titanium core coated with carbon-fiber reinforced polyetheretherketone (peek), combining the strength of titanium with the bone-imitating biomechanical properties and radiolucency of peek. a number of additional features built into the artemis system are designed to facilitate lower-complexity assembly/insertion, as well as reduce the likelihood of implant failure. the objective of this pilot study is to evaluate safety, efficacy and feasibility of the artemis pfn implant for operative fixation of intertrochanteric femoral fractures, compared to matched historical control patients who received other implants.

Eligibility criteria:
inclusion criteria: * all patients with traumatic, non-pathologic stable intertrochanteric fractures requiring cephalomedullary nail fixation exclusion criteria: * pediatric patients (\<18 years) * pregnant females * patients with other concomitant orthopaedic injuries

Keywords: femoral nail cephalomedullary nail artemis proximal femoral nail intertrochanteric femur fractures
phase iii clinical study of mg-k10 humanized mab injection in subjects with prurigo nodularis

Conditions: Prurigo Nodularis

Summary: a phase iii clinical study to evaluate the efficacy and safety of a humanized mg-k10 mab injection in subjects with prurigo nodularis.administered every 4 weeks for 56 weeks.

the study was a multicenter, randomized, double-blind, placebo-controlled phase iii study. approximately 160 adults with prurigo nodularis were scheduled to receive multiple subcutaneous injections (every 4 weeks for 56 weeks). the study was divided into a screening period (1-4 weeks), a double-blind treatment period (24 weeks), a maintenance treatment period (24 weeks), and a follow-up period (8 weeks).

Eligibility criteria:
eligibility criteria: 1. voluntarily sign the icf and comply with all the visits and research-related procedures required by the protocol; 2. both men and women were required to be ≥ 18 and ≤ 80 years old at the time of signing the informed consent; 3. the duration of pn diagnosed by a dermatologist at the time of screening was ≥ 3 months; 4. in the range of 1-10, wi-nrs≥7 in the past 24 h at screening; wi-nrs in the week before the baseline visit the average weekly score was ≥ 7 points. exclusion criteria： 1. there are skin diseases other than pn and mild atopic dermatitis (ad) that may interfere with the assessment of research outcomes. 2. patients who had a history of moderate to severe ad during the 6 months prior to the screening visit or screening visit. 3. receiving potent or super-potent tcs/tci treatment within 2 weeks before or during screening. 4) evidence of active tuberculosis. 5) participation in any other clinical study within 12 weeks or 5 half-lives prior to screening

Keywords: prurigo nodularis